Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | CYP8B1 | Q9UNU6 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ERG | P11308 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2179105 | 0.94 | P2RY12 (0.55) | P2RY12KDM4ECYP8B1HSD17B10HPGD | |
| SCHEMBL1967060 | 0.94 | P2RY12 (0.57) | P2RY12KDM4ECYP8B1HSD17B10HPGD | |
| SCHEMBL1969768 | 0.92 | P2RY12 (0.57) | P2RY12KDM4ECYP8B1MEN1KMT2A | |
| SCHEMBL1969766 | 0.92 | P2RY12 (0.57) | P2RY12KDM4ECYP8B1MEN1KMT2A | |
| SCHEMBL1969147 | 0.91 | P2RY12 (0.58) | P2RY12KDM4ECYP8B1MEN1KMT2A | |
| SCHEMBL1966554 | 0.91 | P2RY12 (0.58) | P2RY12KDM4ECYP8B1MEN1KMT2A | |
| SCHEMBL1967118 | 0.91 | P2RY12 (0.55) | P2RY12KDM4ECYP8B1DPP4MEN1 | |
| SCHEMBL12410018 | 0.90 | P2RY12 (0.57) | P2RY12KDM4ECYP8B1MEN1KMT2A | |
| SCHEMBL1967408 | 0.90 | P2RY12 (0.59) | P2RY12CYP8B1MEN1KMT2A | |
| SCHEMBL1967404 | 0.90 | P2RY12 (0.59) | P2RY12CYP8B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| EP-2334689-A2 | FUSED HETEROCYCLIC COMPOUND | LG Life Sciences Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | F2, PF4, F11 | P2RY12 127/4885KDM4E 3758/4885CYP8B1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.